Christine Heng, Victor Badner, Tasios G. Vakkas, Rosemary Johnson, Yvon Yeo
Abstract
In 2007, more than 5.4 million patients in the United States were taking oral bisphosphonates. However, bisphosphonates are under scrutiny because of the risk of bisphosphonate-related osteonecrosis of the jaw.
OpenAlex reports 7 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
In 2007, more than 5.4 million patients in the United States were taking oral bisphosphonates. However, bisphosphonates are under scrutiny because of the risk of bisphosphonate-related osteonecrosis of the jaw.
Key concepts: Medicine, Osteonecrosis of the jaw, Bisphosphonate, Osteoporosis, Dentistry, Bone Density Conservation Agents, Bone density, Internal medicine